FDA 483 - Sciegen Pharmaceuticals Inc - September 02, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Sciegen Pharmaceuticals Inc. in Hauppauge, NY, identified two significant observations. The firm's written procedures for equipment cleaning and maintenance were found to be inadequate, lacking sufficient detail for methods, materials, and sampling locations. Additionally, several pieces of automatic, mechanical, and electronic equipment, including coating machines used for Clopidogrel and Levetiracetam tablets, were not calibrated across their intended operating ranges.
ID · 500247d4-c1a2-41f6-9bee-15b0e37ef216